Renal Anemia – Current Treatment – Detailed, Expanded Analysis (US)
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist, physicians, patients, and healthcare systems are concerned about their limitations. Delivery, safety issues, and tightening healthcare budgets have resulted in increased scrutiny of the effectiveness and tolerability of renal anemia therapies such as intravenous (IV) iron and erythropoiesis-stimulating agents (ESAs). This content examines the management of dialysis and nondialysis CKD patients from the perspective of nephrologists. It provides a detailed and expanded analysis of the market dynamics and insight into practice patterns, physician attitudes and perceptions, and current and projected use of therapies, including Aranesp, Epogen / Procrit, Mircera, Retacrit, Dexferrum, Feraheme, Ferrlecit, INFeD, Injectafer, Nulecit, Venofer, Auryxia, Monofer, and Triferic. Also discussed are patients’ persistency and compliance with renal anemia medications and the drivers of and obstacles to these agents’ use.
QUESTIONS ANSWERED
- Why do nephrologists switch their patients from IV iron to ESAs?
- At what hemoglobin levels do nephrologists typically initiate ESA therapy?
- How does ESA utilization differ between dialysis and nondialysis renal anemia patients?
- What are the factors that drive / constrain the prescribing of ESAs in renal anemia patients?
CONTENT HIGHLIGHTS
- Geography: United States
- Primary research survey of 101 U.S. nephrologists
- Key drugs / drug classes covered: Aranesp, Epogen / Procrit, Mircera, Retacrit, Dexferrum, Feraheme, Ferrlecit, INFeD, Injectafer, Nulecit, Triferic, Venofer, Auryxia, Monofer
- Key insights provided:
- Factors influencing disease management and treatment decisions.
- Drivers and constraints of treatment selection.
- Physician-reported treatment practices and brand-level patient shares.
- Rationale for treatment switching by therapy / approach.
- Rationale for treatment discontinuation.
- Physician-reported recent / anticipated changes in brand usage or treatment approach.
PRODUCT DESCRIPTION
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Table of contents
- Renal Anemia - Current Treatment - Detailed, Expanded Analysis (US)
- Current Treatment Physician Insights Renal Anemia US August 2021
Tej Pal, M.Pharm., is an analyst on the Cardiovascular, Metabolic, Renal, and Hematologic Diseases team at Clarivate. Previously, he was an analyst at IQVIA and at Smart Analyst Inc., where he worked closely with top pharmaceutical companies on commercial and technical ad-hoc requests. During his tenure there, he delivered competitive landscape and market insight projects on various oncology indications. He holds a master’s degree in pharmacy with a specialization in pharmaceutical chemistry from the Delhi Institute of Pharmaceutical Sciences and Research in New Delhi, India.